Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a report released on Friday. The firm set a “sell” rating on the biotechnology company’s stock.

Evogene Stock Performance

Evogene stock opened at $0.64 on Friday. The firm’s 50-day moving average is $0.69 and its 200-day moving average is $0.77. Evogene has a 1 year low of $0.45 and a 1 year high of $1.44. The company has a market cap of $26.58 million, a P/E ratio of -1.40 and a beta of 1.40.

Evogene (NASDAQ:EVGN) last released its quarterly earnings data on Thursday, May 23rd. The biotechnology company reported ($0.08) earnings per share for the quarter. Evogene had a negative return on equity of 70.96% and a negative net margin of 233.66%. The firm had revenue of $4.19 million during the quarter.

Hedge Funds Weigh In On Evogene

A hedge fund recently raised its stake in Evogene stock. BNP Paribas Financial Markets grew its position in Evogene Ltd. (NASDAQ:EVGN) by 30.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 91,400 shares of the biotechnology company’s stock after buying an additional 21,500 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.22% of Evogene worth $69,000 at the end of the most recent quarter. Institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.